Large HbA1c reduction with Novo's liraglutide

Danish insulin giant Novo Nordisk says that clinical results from the fourth of five Phase III studies with its once-daily human GLP-1 analog, liraglutide, showed that, after a run-in period of metformin and rosiglitazone, more than 50% of the patients in the liraglutide group had reached the American Diabetes Association goal of HbA1c under 7%. Furthermore, more than 35% achieved the American Association of Clinical Endocrinologists HbA1c target of less than or equal to 6.5%. The HbA1c reduction achieved by those on liraglutide was close to 1.5 percentage points compared to baseline. In addition, a weight difference of around 2.5kg versus placebo was observed in favor of liraglutide.